Teva gets FDA nod for generic Xeloda, Sun for generic Prevacid; India's domestic market barely growing;

@EricPFierce: Now that Ranbaxy's Mohali plant falls under FDA consent decree, oversight ramps up significantly. Article | Follow @EricPFierce

> The FDA has approved Teva Pharmaceutical Industries' ($TEVA) generic of Roche's ($RHHBY) Xeloda cancer drug, a product that generated $1.6 billion in sales last year. Story

> Chinese drugmaker Tianyin Pharmaceutical says Chinese authorities have renewed its certificate of good manufacturing practice (GMP) for its pre-extraction plant and formulation facilities. Report

> Sun Pharmaceutical Industries has gotten FDA approval to make a generic of Takeda's Prevacid, a short-term treatment for active duodenal ulcer. Story

> Zydus has launched its patented diabetes drug Lipaglyn in India. Story

> Restructuring at the European Medicines Agency (EMA) will affect plant inspections. Report

And Finally... India's domestic drug market grew just 1.1% in August, the slowest monthly rate recorded. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.